Cedazuridine, also known as E 7727 and WHO 10741, is a cytidine deaminase inhibitor. Decitabine/cedazuridine, sold under the brand name Inqovi, is a fixed-dosed combination medication for the treatment of adults with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). It is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor. Decitabine/cedazuridine was approved for medical use in the United States and in Canada in July 2020.
MedKoo Cat#: 561842
Name: Cedazuridine
CAS#: 1141397-80-9
Chemical Formula: C9H14F2N2O5
Exact Mass: 268.0871
Molecular Weight: 268.21
Elemental Analysis: C, 40.30; H, 5.26; F, 14.17; N, 10.44; O, 29.82
The following data is based on the product molecular weight 268.21 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
